SI1608350T1 - Postopki za preprečevanje, zdravljenje in diagnosticiranje motenj proteinske agregacije - Google Patents

Postopki za preprečevanje, zdravljenje in diagnosticiranje motenj proteinske agregacije

Info

Publication number
SI1608350T1
SI1608350T1 SI200431216T SI200431216T SI1608350T1 SI 1608350 T1 SI1608350 T1 SI 1608350T1 SI 200431216 T SI200431216 T SI 200431216T SI 200431216 T SI200431216 T SI 200431216T SI 1608350 T1 SI1608350 T1 SI 1608350T1
Authority
SI
Slovenia
Prior art keywords
treating
preventing
methods
protein aggregation
diagnosing disorders
Prior art date
Application number
SI200431216T
Other languages
English (en)
Inventor
Joanne Mclaurin
Original Assignee
Joanne Mclaurin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joanne Mclaurin filed Critical Joanne Mclaurin
Publication of SI1608350T1 publication Critical patent/SI1608350T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
SI200431216T 2003-02-27 2004-02-27 Postopki za preprečevanje, zdravljenje in diagnosticiranje motenj proteinske agregacije SI1608350T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US45136303P 2003-02-27 2003-02-27
US52095803P 2003-11-17 2003-11-17
US52353403P 2003-11-19 2003-11-19
US10/787,621 US7521481B2 (en) 2003-02-27 2004-02-26 Methods of preventing, treating and diagnosing disorders of protein aggregation
PCT/CA2004/000272 WO2004075882A1 (en) 2003-02-27 2004-02-27 Methods of preventing, treating and diagnosing disorders of protein aggregation
EP04715226A EP1608350B1 (en) 2003-02-27 2004-02-27 Methods of preventing, treating and diagnosing disorders of protein aggregation

Publications (1)

Publication Number Publication Date
SI1608350T1 true SI1608350T1 (sl) 2009-12-31

Family

ID=32931587

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200432169T SI2311445T1 (sl) 2003-02-27 2004-02-27 Postopki preventive, zdravljenja in diagnosticiranja kopičenja proteinov
SI200432192T SI2153829T1 (sl) 2003-02-27 2004-02-27 Postopki preventive, zdravljenja in diagnosticiranja kopičenja proteinov
SI200431216T SI1608350T1 (sl) 2003-02-27 2004-02-27 Postopki za preprečevanje, zdravljenje in diagnosticiranje motenj proteinske agregacije

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI200432169T SI2311445T1 (sl) 2003-02-27 2004-02-27 Postopki preventive, zdravljenja in diagnosticiranja kopičenja proteinov
SI200432192T SI2153829T1 (sl) 2003-02-27 2004-02-27 Postopki preventive, zdravljenja in diagnosticiranja kopičenja proteinov

Country Status (15)

Country Link
US (7) US7521481B2 (sl)
EP (4) EP1608350B1 (sl)
JP (4) JP4999453B2 (sl)
AT (1) ATE432694T1 (sl)
AU (2) AU2004216544B2 (sl)
BR (1) BRPI0407910A (sl)
CA (1) CA2516563C (sl)
CY (2) CY1109338T1 (sl)
DE (1) DE602004021362D1 (sl)
DK (3) DK2311445T3 (sl)
ES (3) ES2327521T3 (sl)
IL (2) IL170476A (sl)
PT (3) PT2153829E (sl)
SI (3) SI2311445T1 (sl)
WO (1) WO2004075882A1 (sl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046334A2 (en) * 2002-11-19 2004-06-03 Board Of Trustees Operating Michigan State University Antioxidant and antimicrobial agents and methods of use thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
JP5148873B2 (ja) 2003-06-27 2013-02-20 エチコン、インコーポレイテッド 臍帯組織由来の分娩後細胞、及びその作成及び使用方法
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7840270B2 (en) * 2003-07-23 2010-11-23 Synapse Biomedical, Inc. System and method for conditioning a diaphragm of a patient
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
US20060189582A1 (en) * 2004-11-17 2006-08-24 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
JP2009511568A (ja) * 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
NO346055B1 (no) * 2005-12-12 2022-01-24 Ac Immune Sa Antigen konstruksjon, vaksinesammensetning og fremgangsmåte for produksjon derav.
WO2007129221A2 (en) * 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
JP2009529502A (ja) * 2006-03-09 2009-08-20 ワラタ ファーマシューティカルズ， インコーポレイテッド タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物
WO2008002465A2 (en) * 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20100292157A1 (en) * 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
DK2148667T3 (da) * 2007-04-12 2013-08-26 Waratah Pharmaceuticals Inc Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
CA2683546A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
CA2683580A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
WO2008144578A1 (en) * 2007-05-17 2008-11-27 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
WO2009059033A1 (en) * 2007-10-30 2009-05-07 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
US20090131857A1 (en) * 2007-11-20 2009-05-21 Mark Geiger Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid
AT506535B1 (de) 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
MX2010010314A (es) * 2008-03-21 2011-04-12 Gen Hospital Corp Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados.
KR101021078B1 (ko) 2008-07-22 2011-03-14 포항공과대학교 산학협력단 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물
JP2012505162A (ja) * 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ， インコーポレイテッド 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用
GB0821994D0 (en) * 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
AU2010229651B2 (en) 2009-03-26 2014-05-08 Advanced Technologies And Regenerative Medicine, Llc Human umbilical cord tissue cells as therapy for Alzheimer' s disease
WO2010110923A2 (en) * 2009-03-27 2010-09-30 Robert Sabin Prophylactic and therapeutic treatment of alzheimer's disease
EP2545023A4 (en) * 2010-02-15 2017-04-12 Abbvie Inc. Process for the preparation of scyllo-inositol
WO2012051395A1 (en) 2010-10-13 2012-04-19 Elan Pharmaceuticals, Inc. Methods of synthesis of scyllitol and related compounds
US9116157B2 (en) 2010-11-05 2015-08-25 Brandeis University Ice-cleaved alpha-synuclein as a biomarker
RU2013154699A (ru) * 2011-06-03 2015-07-20 Транзишн Терапевтикс Айрленд Лимитед Сцилло-инозитол для применения в лечении поведенческих и психических расстройств
KR101365711B1 (ko) * 2013-04-30 2014-02-21 재단법인 경북해양바이오산업연구원 효모로부터 분리된 신규한 생물학적 계면활성제
WO2015200706A1 (en) 2014-06-25 2015-12-30 Rensselaer Polytechnic Institute Oxetane polymers and methods of preparation thereof
WO2016047823A1 (ko) * 2014-09-25 2016-03-31 영남대학교 산학협력단 장구채 추출물 또는 이로부터 분리된 보르네시톨을 유효성분으로 함유하는 세포 노화 억제용 조성물
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US20170354669A1 (en) * 2016-02-24 2017-12-14 The Trustees Of Columbia University In The City Of New York Disruption of the interaction between amyloid beta peptide and dietary lipids
AU2017318672B2 (en) 2016-09-01 2022-03-10 Nutrition 21, Llc Magnesium biotinate compositions and methods of use
WO2018191415A1 (en) 2017-04-11 2018-10-18 Colorado State University Research Foundation Functionalization of metal-organic frameworks
WO2019222454A1 (en) 2018-05-16 2019-11-21 Emory University Styrylbenzothiazole derivatives and uses in imaging
CA3118583C (en) * 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation
EP3789018A1 (en) * 2019-09-09 2021-03-10 Servicio Andaluz De Salud Composition and methods for enhancing or promoting the secretion of ghrelin to promote a healthy metabolic aging
AU2020407071A1 (en) 2019-12-16 2022-07-07 Nutrition 21, Llc Methods of production of arginine-silicate complexes
BR112022013296A2 (pt) * 2020-01-03 2022-09-06 Biosearch S A Composição para uso no tratamento de transtornos cognitivos
JPWO2022059776A1 (sl) * 2020-09-17 2022-03-24
WO2024054415A1 (en) * 2022-09-07 2024-03-14 Eirgen Pharma, Ltd. A combination of scyllo-inositol and flavones

Family Cites Families (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2088897A (en) * 1935-03-25 1937-08-03 Goss Printing Press Co Ltd Printing press
US2557381A (en) * 1946-08-09 1951-06-19 William C Huebner Multiple unit printing press
DE2234089C3 (de) * 1972-07-08 1975-01-23 Automatic Druckmaschinenfabrik Dr. W. Hinniger U. Soehne, 1000 Berlin Offset-Rollen-Rotationsdruckmaschine
GB1581233A (en) * 1976-06-02 1980-12-10 Drg Uk Ltd Printing press
US4201706A (en) * 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
DE3405663A1 (de) 1984-02-17 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung von scyllo-inosit
US5023248A (en) 1984-10-23 1991-06-11 Perstorp Ab Method of treating diabetes with inositol triphosphate
US4735902A (en) 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
SE465305B (sv) 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel
US5330979A (en) 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5407924A (en) 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
SE465951B (sv) 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5545632A (en) 1984-10-23 1996-08-13 Perstorp Ab Method of treating retroviral disease
US5128332A (en) 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3610107A1 (de) * 1986-03-26 1987-10-08 Voith Gmbh J M Stellvorrichtung zum verstellen einer walze
US5135923A (en) 1986-04-16 1992-08-04 Perstorp Ab Method of treating cardiovascular diseases
US5057507A (en) 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
US4758420A (en) * 1986-07-14 1988-07-19 The Dow Chemical Company Solvent extraction of polychlorinated organic compounds from porous materials
US4952396A (en) 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
JPH067158Y2 (ja) 1987-03-18 1994-02-23 株式会社藤井合金製作所 配管端末の防水構造
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3808142A1 (de) * 1988-03-11 1989-09-21 Goebel Gmbh Maschf Lagereinrichtung
DE3814752C1 (sl) * 1988-04-30 1989-08-31 J.M. Voith Gmbh, 7920 Heidenheim, De
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
JPH03102492A (ja) 1989-06-12 1991-04-26 Mitsui Eng & Shipbuild Co Ltd 自動販売機のデータ送信システムおよび複合機能型自動販売機
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5111814A (en) * 1990-07-06 1992-05-12 Thomas Jefferson University Laryngeal pacemaker
US5217959A (en) 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
JP2984043B2 (ja) 1990-09-18 1999-11-29 旭化成工業株式会社 ミオ・イノシトールデヒドロゲナーゼおよびその製造法
US5112814A (en) 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
JPH05192163A (ja) 1991-09-30 1993-08-03 Suntory Ltd イノシトールデヒドロゲナーゼ遺伝子
ATE128708T1 (de) 1991-12-18 1995-10-15 Schering Corp Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten.
SE469260B (sv) 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
JP3251976B2 (ja) 1992-06-23 2002-01-28 旭化成株式会社 ミオ・イノシトールデヒドロゲナーゼを生産する実質上純粋な微生物
US5351616A (en) * 1992-08-13 1994-10-04 Man Roland Druckmaschinen Ag Rotary web printing machine, particularly for printing on thick or carton-type stock webs with replaceable plate cylinders
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
JP4242925B2 (ja) 1992-10-05 2009-03-25 バージニア テック インテレクチュアル プロパティース インコーポレイテッド Ｄ−ｃｈｉｒｏ−３−イノソース及び▲（＋）▼−Ｄ−ｃｈｉｒｏ−イノシトールの合成
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
DK0619369T3 (da) 1993-04-05 2003-10-06 Aveve Nv Phytathydrolyse og enzymsammensætning til hydrolyse af phytat
WO1995004711A1 (fr) 1993-08-11 1995-02-16 Hokko Chemical Industry Co., Ltd. Procede de production de d-chiro-inositol
US5412080A (en) 1993-08-25 1995-05-02 President And Fellow Of Harvard College Enterobactin compounds
SE502574C2 (sv) 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
DE4408025A1 (de) * 1994-03-10 1995-09-14 Koenig & Bauer Ag Druckwerk für eine Mehrfarbenrollenrotationsdruckmaschine
DE4430693B4 (de) * 1994-08-30 2005-12-22 Man Roland Druckmaschinen Ag Antriebe für eine Rollenrotations-Offsetdruckmaschine
US5550166A (en) 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US5858326A (en) 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US6221645B1 (en) * 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP3630344B2 (ja) 1995-11-17 2005-03-16 北興化学工業株式会社 イノシトール立体異性体の製造方法
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
US6232486B1 (en) 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US5977078A (en) 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
DK0966277T3 (da) 1997-03-10 2006-03-27 Univ Loma Linda Med Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
US5998485A (en) 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
GB9801899D0 (en) 1998-01-29 1998-03-25 Univ London Neurotrophic properties of ipgs analogues
DE19805898C2 (de) * 1998-02-13 2003-09-18 Roland Man Druckmasch Druckwerk für eine Rollenrotationsdruckmaschine
US6720190B1 (en) * 1998-03-27 2004-04-13 Ole Hindsgaul Methods for screening compound libraries
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US6227110B1 (en) * 1998-06-23 2001-05-08 Heidelberger Druckmaschinen Ag Wet printing press with throw-off mechanism
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
AUPP589398A0 (en) 1998-09-14 1998-10-08 Walter And Eliza Hall Institute Of Medical Research, The Immunogenic compositions and uses thereof
WO2000017369A2 (en) 1998-09-24 2000-03-30 Pharmacia & Upjohn Company Alzheimer's disease secretase
AUPP675898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of activating t cells and agents useful for same
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
NZ534876A (en) * 1999-02-10 2006-02-24 Elan Pharm Inc Human beta-secretase enzyme, inhibitors and their compositions and uses
GB2389113B (en) 1999-02-10 2004-02-04 Elan Pharm Inc B-secretase inhibitor
KR20020006626A (ko) 1999-02-26 2002-01-23 폴락 돈나 엘. 신규한 술폰아미드 화합물 및 그의 용도
US6818430B1 (en) 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6864240B1 (en) * 1999-06-15 2005-03-08 Elan Pharmaceuticals, Inc. Dipeptide inhibitors of β-secretase
AU5619400A (en) 1999-06-15 2001-01-02 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase
CA2375628A1 (en) 1999-07-09 2001-01-18 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
DE19937803A1 (de) * 1999-08-10 2001-02-15 Roland Man Druckmasch Druckwerk
DE19937796B4 (de) * 1999-08-10 2007-03-22 Man Roland Druckmaschinen Ag Druckwerk
DE19937805A1 (de) * 1999-08-10 2001-02-15 Roland Man Druckmasch Druckwerk
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6329256B1 (en) 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
JP2001163810A (ja) 1999-09-30 2001-06-19 Microbial Chem Res Found １ｄ−キロ−イノシトールの新規合成方法および中間体
MXPA02003861A (es) 1999-10-18 2003-07-14 Muscletech Res And Dev Inc Suplemento alimenticio para incrementar la masa sin desarrollar y la fuerza.
US7728043B2 (en) * 1999-10-22 2010-06-01 Kim Darrick S H L Methods for treatment of beta-amyloid protein-induced ocular disease
WO2001034571A1 (en) 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
CA2388750A1 (en) 1999-11-09 2001-05-17 James Edmund Audia .beta.-aminoacid compounds useful for inhibiting .beta.-amyloid peptide release and/or its synthesis
DE19963944C1 (de) * 1999-12-31 2001-06-13 Koenig & Bauer Ag Verfahren zum Einstellen einer Walze einer Druckmaschine
AU779875B2 (en) * 2000-01-24 2005-02-17 Merck Sharp & Dohme Limited Gamma-secretase inhibitors
DE10008215B4 (de) * 2000-02-23 2013-03-28 Manroland Web Systems Gmbh Druckwerk für eine Rotationsdruckmaschine mit Kreuzschlitten
GB0005251D0 (en) * 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
WO2001066096A2 (en) 2000-03-06 2001-09-13 Immune Network Ltd. Compositions for prevention and treatment of dementia
CA2404125C (en) 2000-03-20 2011-01-25 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
CA2401749A1 (en) * 2000-03-23 2001-09-27 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
GB0008710D0 (en) * 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
EP1284729A4 (en) 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US6716826B2 (en) * 2000-05-12 2004-04-06 Rodaris Pharmaceuticals Limited Compounds and their uses
US6939857B2 (en) * 2000-05-12 2005-09-06 Rodaris Pharmaceuticals Limited Compounds and their uses
AU2001258771A1 (en) 2000-05-19 2001-11-26 Takeda Chemical Industries Ltd. -secretase inhibitors
GB0015627D0 (en) 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
ATE302751T1 (de) 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
DE10031955A1 (de) 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
GB0016681D0 (en) * 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6559891B1 (en) * 2000-08-15 2003-05-06 Sony Corporation Method and apparatus to generate tri-level HDTV synchronization pulses
EP1349858B1 (en) 2000-11-02 2008-08-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
AU2002210747B2 (en) 2000-11-02 2006-06-01 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
JP3887600B2 (ja) 2001-01-15 2007-02-28 北興化学工業株式会社 Ｄ−ミオ−イノシトール１−エピメラーゼをコードするｄｎａ
EP1357912B9 (en) * 2001-02-06 2012-06-13 QLT Inc. Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
EP1233021A3 (en) * 2001-02-20 2002-11-20 Pfizer Products Inc. An inhibitor of Beta amyloid cleavage enzyme
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
KR100564781B1 (ko) * 2001-04-09 2006-03-27 쾨니히 운트 바우어 아크티엔게젤샤프트 인쇄기의 인쇄 장치
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
DE60229846D1 (de) 2001-05-22 2008-12-24 Merck & Co Inc Beta-secretase-substrat und seine verwendung
EP1392645A2 (en) * 2001-05-22 2004-03-03 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
WO2002098849A2 (en) 2001-06-01 2002-12-12 Elan Pharmaceuticals, Inc. Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer’s disease and similar diseases
US6684775B2 (en) * 2001-06-07 2004-02-03 Heidelberger Druckmaschinen Ag Printing unit with roll-away inkers
US20050130941A1 (en) 2001-06-08 2005-06-16 Heinrich Schostarez Methods of treating alzheimer's disease
EP1406862A1 (en) 2001-06-11 2004-04-14 Elan Pharmaceuticals, Inc. Substituted aminoalcohols useful in treatment of alzheimer's disease
BR0210391A (pt) 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE323084T1 (de) 2001-06-12 2006-04-15 Elan Pharm Inc Für die behandlung von alzheimer krankheit geeignete makrocyclen
JP2004532894A (ja) 2001-06-13 2004-10-28 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療するためのアミンジオール
JP3981597B2 (ja) 2001-06-25 2007-09-26 北興化学工業株式会社 シロ−イノソースの製造法及びシロ−イノシトールの製造法
JP2005500310A (ja) 2001-06-25 2005-01-06 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療するためのビシクロ化合物の使用
JP2005500319A (ja) 2001-06-27 2005-01-06 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用なβ−ヒドロキシアミン誘導体
BR0211122A (pt) 2001-07-10 2004-10-26 Elan Pharm Inc Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US7053109B2 (en) 2001-07-10 2006-05-30 Pharmacia & Upjohn Company Aminediols for the treatment of Alzheimer's disease
WO2003006013A1 (en) 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US6599891B2 (en) * 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
MXPA04001016A (es) 2001-08-03 2004-05-27 Schering Corp Derivados de sulfonamida como inhibidores de la gamma secretasa.
AU2002324582B9 (en) * 2001-08-03 2006-02-16 Schering Corporation Novel gamma secretase inhibitors
JP2005506979A (ja) 2001-08-28 2005-03-10 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー オキソ置換及びヒドロキシ置換炭化水素のキナルドイル−アミン誘導体を使用するアルツハイマー病の治療方法
DE10145322A1 (de) * 2001-09-14 2003-04-03 Ina Schaeffler Kg Lageranordnung für Zylinder, Walzen oder Trommeln
US20060100196A1 (en) 2001-09-24 2006-05-11 Andrea Gailunas Substituted amines for the treatment of alzheimer's disease
WO2003029169A2 (en) 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
BR0213138A (pt) 2001-10-05 2004-08-24 Elan Pharm Inc Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto
AU2002359301B2 (en) 2001-10-23 2008-07-03 Comentis, Inc. Beta-secretase inhibitors and methods of use
MXPA04004079A (es) 2001-10-29 2005-07-05 Pharmacia & Upjohn Co Llc Amidas hidroxi sustituidas para tratamiento de enfermedad de alzheimer.
AU2002359376B2 (en) 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
NZ533158A (en) 2001-11-19 2006-09-29 Elan Pharm Inc 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines
CA2477585A1 (en) 2001-11-21 2003-06-05 Elan Pharmaceuticals, Inc. Amino acid derivatives useful for the treatment of alzheimer's disease
EP1450795A1 (en) 2001-12-04 2004-09-01 Elan Pharmaceuticals, Inc. Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
WO2003050073A1 (en) 2001-12-06 2003-06-19 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
CH698246B1 (de) 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
EP1458745A2 (en) 2002-01-04 2004-09-22 Elan Pharmaceuticals, Inc. SUBSTITUTED AMINO CARBOXAMIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL162838A0 (en) * 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
EP1467729A1 (en) 2002-01-18 2004-10-20 The Genetics Company Inc. Beta-secretase inhibitors
US7053220B2 (en) 2002-02-01 2006-05-30 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
US7256186B2 (en) * 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
AU2003235283A1 (en) 2002-04-24 2003-11-10 Hiroshi Mori Gamma-secretase inhibitors
DE60328182D1 (de) * 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
AU2003229024A1 (en) 2002-05-07 2003-11-11 Elan Pharmaceuticals, Inc. Succinoyl aminopyrazoles and related compounds
DE10223666B4 (de) * 2002-05-28 2006-06-14 Windmöller & Hölscher Kg Farbwerksaufbau bei Flexodruckmaschinen
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
WO2003103653A1 (en) 2002-06-11 2003-12-18 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
AU2003237546A1 (en) 2002-06-11 2003-12-22 Elan Pharmaceuticals, Inc. METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED Omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
WO2004002478A1 (en) 2002-06-27 2004-01-08 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
GB0217909D0 (en) 2002-08-01 2002-09-11 Du Pont Chintzed stretch fabrics
GB0218041D0 (en) 2002-08-02 2002-09-11 Merck Sharp & Dohme Chemical process
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
MXPA05002508A (es) 2002-09-06 2005-06-03 Elan Pharm Inc Derivados de profarmaco 1,3-diamino-2-hidroxipropano.
UY27967A1 (es) 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
WO2004029019A2 (en) 2002-09-27 2004-04-08 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer’s disease
BR0306491A (pt) 2002-09-30 2004-10-13 Bp Corp North America Inc Método e sistema para fornecer potência para compressão de refrigerante e potência elétrica compartilhada para um processo de liquefação de gás de hidrocarbonetos leves, com reduzidas emissões de dióxido de carbono
EP1545582A4 (en) 2002-10-01 2008-09-17 Univ Northwestern DIFFUSIBLE DERIVATIVES DERIVED FROM AMYLOID BETA (ADDL), ADDL SUBSTITUTE, ADDL BINDING MOLECULES, AND USES THEREOF
GB0223038D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
WO2004039759A1 (fr) * 2002-10-17 2004-05-13 Sun, Mingjie Compose naturel servant dans le traitement de diabetes, sa preparation et son utilisation
PE20040762A1 (es) 2002-11-27 2004-11-06 Elan Pharm Inc Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer
WO2004052348A2 (en) 2002-12-11 2004-06-24 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
FR2848452B1 (fr) 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
JP4662914B2 (ja) 2003-02-04 2011-03-30 エフ．ホフマン−ラ ロシュ アーゲー ガンマ−セクレターゼ阻害剤としてのマロンアミド誘導体
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0308318D0 (en) 2003-04-10 2003-05-14 Merck Sharp & Dohme Therapeutic agents
EP1615915A1 (en) 2003-04-21 2006-01-18 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
TW200512195A (en) 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
DE602004015110D1 (de) * 2003-05-13 2008-08-28 Schering Corp Verbrückte n-arylsulfonylpiperidine als gamma-sekretaseinhibitoren
US7410964B2 (en) 2003-05-16 2008-08-12 Merck Sharp & Dohme Ltd. Cyclohexyl sulphones as gamma-secretase inhibitors
US7060698B2 (en) 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
WO2005009344A2 (en) 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
WO2005004802A2 (en) 2003-06-30 2005-01-20 Merck & Co., Inc. N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
CA2530006A1 (en) 2003-07-01 2005-01-20 Merck & Co., Inc. Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
EP1671129A1 (en) 2003-07-21 2006-06-21 Angiogenetics Sweden AB Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
ES2323068T3 (es) 2003-08-08 2009-07-06 Schering Corporation Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida.
WO2005018545A2 (en) 2003-08-14 2005-03-03 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
EP1667984B1 (en) 2003-09-24 2011-05-18 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
WO2005032471A2 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
GB0323258D0 (en) * 2003-10-04 2003-11-05 Merck Sharp & Dohme Therapeutic compounds
ES2548720T3 (es) 2003-10-06 2015-10-20 F. Hoffmann-La Roche Ag Derivados de dibenzoazepina y benzodiazepina sustituidos útiles como inhibidores de la gamma-secretasa
EP2058390B1 (en) 2003-10-14 2013-01-23 Hokko Chemical Industry Co., Ltd. Method for producing scyllo-inositol
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0326039D0 (en) * 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
JP4451449B2 (ja) 2003-11-11 2010-04-14 エフ．ホフマン−ラ ロシュ アーゲー ホスフィン酸誘導体、アルツハイマー病の処置のためのベータセクレターゼインヒビタ
ATE517861T1 (de) 2003-11-24 2011-08-15 Merck Sharp & Dohme Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
CN1886391A (zh) 2003-11-28 2006-12-27 弗·哈夫曼-拉罗切有限公司 作为β－分泌酶抑制剂的特仑酸和特拉氨酸
CA2548849A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005063796A1 (en) 2003-12-31 2005-07-14 Posco Inhibitors of amyloid precursor protein processing
DE602004011400T2 (de) 2004-01-29 2009-01-22 Cellzome Ag Behandlung von neurodegenerativen krankheiten mit gpr49
CN1934251A (zh) 2004-01-29 2007-03-21 塞尔卓姆股份公司 使用atp7a－调控剂治疗神经变性疾病
WO2005095326A2 (en) 2004-03-25 2005-10-13 Elan Pharmaceuticals, Inc. 2-amino- and 2-thio-substituted 1,3-diaminopropanes
US20070203147A1 (en) 2004-03-30 2007-08-30 Coburn Craig A 2-Aminothiazole Compounds Useful As Aspartyl Protease Inhibitors
KR20070010144A (ko) 2004-04-05 2007-01-22 쉐링 코포레이션 신규한 감마 세크레타제 억제제
EP1740581B1 (en) 2004-04-20 2012-08-22 Merck Sharp & Dohme Corp. 2, 4, 6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
EP1740559B1 (en) 2004-04-20 2014-10-15 Merck Sharp & Dohme Corp. 1,3,5-substituted phenyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
JP2007537257A (ja) * 2004-05-13 2007-12-20 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療用ベータセクレターゼ阻害剤として有用なフェニルカルボキサミド化合物
US20060004096A1 (en) * 2004-05-28 2006-01-05 Joseph Larner Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
JP4406327B2 (ja) 2004-06-29 2010-01-27 儀昭 新田 タイヤチップ製造装置
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
US20060189582A1 (en) 2004-11-17 2006-08-24 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
WO2006088705A1 (en) 2005-02-14 2006-08-24 Wyeth Terphenyl guanidines as [beta symbol] -secretase inhibitors
WO2006112000A1 (ja) 2005-03-30 2006-10-26 The Niigata Institute Of Science And Technology 大腸菌変異株による２－デオキシ－シロ－イノソースの合成および精製する方法並びに得られた２－デオキシ－シロ－イノソース
KR20060105233A (ko) 2005-04-02 2006-10-11 삼성전자주식회사 하이브리드 디스크, 그 기록 및/또는 재생 장치 및 방법
US7273882B2 (en) 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
US20090182021A1 (en) 2005-08-03 2009-07-16 Nanternet Philippe G Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
WO2007021793A1 (en) 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
JP2009511568A (ja) 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
PL1966198T3 (pl) * 2005-10-25 2011-07-29 Janssen Pharmaceutica Nv Pochodne 2-amino-3,4-dihydropirydo[3,4-d]pirymidyny do zastosowania jako inhibitory beta-sekretazy (BACE)
CA2579188A1 (en) 2006-02-17 2007-08-17 Joanne Mclaurin Treatment of amyloid-related diseases
US20070197452A1 (en) 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
WO2007129221A2 (en) 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
JP2009529502A (ja) 2006-03-09 2009-08-20 ワラタ ファーマシューティカルズ， インコーポレイテッド タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物
WO2007134434A1 (en) 2006-05-18 2007-11-29 Merck Frosst Canada Ltd. Phenanthrene derivatives as mpges-1 inhibitors
WO2007134449A1 (en) 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
EP1884531A1 (en) 2006-07-30 2008-02-06 Lonza Compounds GmbH & Co. KG Sheet molding compounds (smc) comprising thermosetting resins based on renewable resources
WO2008024930A2 (en) 2006-08-25 2008-02-28 Allan Basbaum Intrathecal administration of triptan compositions to treat non-migraine pain
US20100256752A1 (en) 2006-09-06 2010-10-07 Forster David C Prosthetic heart valves, support structures and systems and methods for implanting the same,
WO2008034244A1 (en) 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
US20100292157A1 (en) 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
CA2674048A1 (en) 2006-12-29 2008-07-10 Normoxys, Inc. Cyclitols and their derivatives and their therapeutic applications
WO2008098371A1 (en) 2007-02-16 2008-08-21 The Royal Institution For The Advancement Of Learning/Mcgill University Compositions and method for reducing amyloid beta in a mammal
DK2148667T3 (da) 2007-04-12 2013-08-26 Waratah Pharmaceuticals Inc Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
CA2683546A1 (en) 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
US20110105626A1 (en) 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
CA2683580A1 (en) 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
JP5034916B2 (ja) 2007-12-10 2012-09-26 富士通セミコンダクター株式会社 性能評価モデル生成方法、システム性能評価方法、及び性能評価モデル生成装置
KR20110040972A (ko) 2008-08-06 2011-04-20 인비스타 테크놀러지스 에스.에이.알.엘. 일회용 위생용품 및 의류의 성분에 유용한 탄성 복합 구조물의 제조 방법
CA2737163C (en) 2008-09-15 2019-03-12 Elan Pharmaceuticals, Inc. Methods of treatment of hyperuricemia and associated disease states
JP2012505162A (ja) 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ， インコーポレイテッド 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用
RU2013154699A (ru) 2011-06-03 2015-07-20 Транзишн Терапевтикс Айрленд Лимитед Сцилло-инозитол для применения в лечении поведенческих и психических расстройств

Also Published As

Publication number Publication date
JP2016117743A (ja) 2016-06-30
DE602004021362D1 (de) 2009-07-16
US20120157549A1 (en) 2012-06-21
US20140073701A1 (en) 2014-03-13
US7521481B2 (en) 2009-04-21
CA2516563A1 (en) 2004-09-10
US20150031776A1 (en) 2015-01-29
WO2004075882A1 (en) 2004-09-10
CA2516563C (en) 2013-08-20
EP2153829A1 (en) 2010-02-17
AU2009251035A1 (en) 2010-01-14
US20070078099A1 (en) 2007-04-05
DK2153829T3 (da) 2014-10-27
CY1109338T1 (el) 2014-07-02
US8859628B2 (en) 2014-10-14
AU2004216544B2 (en) 2009-09-24
DK1608350T3 (da) 2009-09-07
US9833420B2 (en) 2017-12-05
JP2014065731A (ja) 2014-04-17
EP2311445A1 (en) 2011-04-20
EP2153829B1 (en) 2014-08-13
JP2011105733A (ja) 2011-06-02
PT1608350E (pt) 2009-08-28
IL170476A (en) 2013-05-30
ES2475977T3 (es) 2014-07-11
ATE432694T1 (de) 2009-06-15
SI2311445T1 (sl) 2014-08-29
IL220065A (en) 2015-08-31
EP2311445B1 (en) 2014-03-26
CY1115732T1 (el) 2017-01-25
US20150164821A1 (en) 2015-06-18
DK2311445T3 (da) 2014-06-16
IL220065A0 (en) 2012-09-24
AU2009251035B2 (en) 2012-12-13
PT2311445E (pt) 2014-06-25
JP4999453B2 (ja) 2012-08-15
US20090227686A1 (en) 2009-09-10
PT2153829E (pt) 2014-10-16
EP1608350B1 (en) 2009-06-03
EP2823813A1 (en) 2015-01-14
US20040204387A1 (en) 2004-10-14
BRPI0407910A (pt) 2006-02-14
SI2153829T1 (sl) 2014-12-31
JP2006522740A (ja) 2006-10-05
AU2004216544A1 (en) 2004-09-10
EP1608350A1 (en) 2005-12-28
ES2327521T3 (es) 2009-10-30
ES2520047T3 (es) 2014-11-11

Similar Documents

Publication Publication Date Title
IL220065A0 (en) Methods of preventing, treating and diagnosing disorders of protein aggregation
MX2007005870A (es) Composiciones que comprenden derivados de escilo-inositol y metodos para tratar trastornos de agregacion de proteinas.
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
WO2002096415A3 (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
DE602004027888D1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihr
EP2332569A3 (en) Compositions and methods for treating neurological disorders
HK1083203A1 (en) The use of intratumorally administered lactoferrin in the treatment of malignant neoplasms
WO2005066337A3 (en) Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
IL197890A (en) Arylvinylchloroalkylan compounds and their preparation methods and uses
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
ZA201106419B (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2007129221A8 (en) Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
WO2005060945A3 (en) Intranasal compositions comprising zolpidem
WO2001092274A3 (en) Naaladase inhibitors for treating retinal disorders and glaucoma
DE60327634D1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
JP2003526659A5 (sl)
WO2002102412A3 (en) Selective inhibition of intracellular amyloid-beta neurotoxicity in human neurons
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
WO2004112705A3 (en) Methods for treating sleep disorders
WO2006108128A3 (en) Ocular delivery of interferon-tau